Puma Biotechnology (PBYI) to Release Earnings on Thursday

Posted by Bob Marten on Apr 30th, 2024

Puma Biotechnology (NASDAQ:PBYI – Get Free Report) will be releasing its earnings data after the market closes on Thursday, May 2nd. Analysts expect Puma Biotechnology to post earnings of ($0.16) per share for the quarter. Puma Biotechnology has set its Q1 2024 guidance at EPS and its FY 2024 guidance at EPS.Parties that wish to listen to the company’s conference call can do so using this link.

Puma Biotechnology (NASDAQ:PBYI – Get Free Report) last announced its earnings results on Thursday, February 29th. The biopharmaceutical company reported $0.26 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.07). The firm had revenue of $72.20 million during the quarter, compared to the consensus estimate of $73.22 million. Puma Biotechnology had a return on equity of 58.21% and a net margin of 9.16%. On average, analysts expect Puma Biotechnology to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Puma Biotechnology Stock Performance

PBYI stock opened at $5.02 on Tuesday. The firm has a 50-day simple moving average of $5.46 and a two-hundred day simple moving average of $4.62. The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.50 and a current ratio of 1.57. Puma Biotechnology has a one year low of $2.13 and a one year high of $7.73. The firm has a market cap of $242.01 million, a price-to-earnings ratio of 10.91, a PEG ratio of 2.86 and a beta of 1.28.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. StockNews.com cut shares of Puma Biotechnology from a “buy” rating to a “hold” rating in a research report on Wednesday, April 10th. HC Wainwright decreased their price objective on Puma Biotechnology from $8.00 to $7.00 and set a “buy” rating for the company in a report on Friday, March 1st.

View Our Latest Research Report on Puma Biotechnology

Puma Biotechnology Company Profile

(Get Free Report)

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.